[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.187.2. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1961

Tropicamide as a Cycloplegic Agent

Author Affiliations

St. Louis
From the Department of Ophthalmology and the Oscar Johnson Institute, Washington University School of Medicine.

Arch Ophthalmol. 1961;66(1):70-72. doi:10.1001/archopht.1961.00960010072015
Abstract

The importance of cycloplegia in refraction is attested to by the continuing search for the ideal cycloplegic drug. This ideal drug should provide (1) maximum relaxation of accommodation; (2) satisfactory mydriasis; (3) rapid onset of action and rapid attainment of maximum effect; (4) short duration and rapid recovery; (5) consistency in its effectiveness; (6) freedom from toxicity, irritation, or sensitivity.

For many decades, homatropine was the drug of choice for cycloplegia in refraction. Several newer drugs have far surpassed homatropine in all of the above qualifications except one. Unfortunately that one is the first and most important of all—maximum cycloplegic effect1! The search goes on.

Recently, tropicamide * has claimed the attention of investigators and clinicians. Tropicamide is a parasympatholytic drug (N-ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide). It was introduced on the European continent, and has been reported on recently in the American literature.2,3 Merrill et al.,2 in a study of 262 patients

First Page Preview View Large
First page PDF preview
First page PDF preview
×